Vera Therapeutics (VERA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vera Therapeutics (VERA)
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Key Insights
Critical company metrics and information
Share Price
$49.46Market Cap
$3.13 BillionTotal Outstanding Shares
63.32 Million SharesTotal Employees
82Dividend
No dividendIPO Date
May 14, 2021SIC Description
Pharmaceutical PreparationsHomepage
https://www.veratx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $305.55 Million |
Net Cash Flow From Operating Activities | $-120.64 Million |
Net Cash Flow From Investing Activities, Continuing | $-185.09 Million |
Net Cash Flow From Operating Activities, Continuing | $-120.64 Million |
Net Cash Flow | $185000.00 |
Net Cash Flow, Continuing | $185000.00 |
Net Cash Flow From Financing Activities, Continuing | $305.55 Million |
Net Cash Flow From Investing Activities | $-185.09 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Available To Common Stockholders, Basic | $-134.38 Million |
Revenues | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-134.38 Million |
Nonoperating Income/Loss | $10.91 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Diluted Average Shares | $54.12 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss | $-134.38 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Basic Earnings Per Share | $2.61 |
Other Operating Expenses | $31.67 Million |
Research and Development | $113.61 Million |
Operating Income/Loss | $-145.28 Million |
Income/Loss From Continuing Operations After Tax | $-134.38 Million |
Basic Average Shares | $54.12 Million |
Operating Expenses | $145.28 Million |
Net Income/Loss Attributable To Parent | $-134.38 Million |
Diluted Earnings Per Share | $2.61 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $364.13 Million |
Long-term Debt | $50.47 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Current Liabilities | $18.22 Million |
Noncurrent Liabilities | $53.04 Million |
Accounts Payable | $4.60 Million |
Liabilities | $79.50 Million |
Liabilities And Equity | $368.56 Million |
Equity Attributable To Parent | $289.06 Million |
Other Non-current Liabilities | $2.57 Million |
Fixed Assets | $368000.00 |
Equity | $289.06 Million |
Other Non-current Assets | $4.06 Million |
Current Liabilities | $26.46 Million |
Wages | $3.64 Million |
Assets | $368.56 Million |
Noncurrent Assets | $4.43 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.